Institute of Chemical Biology expands leadership
Gary Sulikowski, Ph.D.
Brian Bachmann, Ph.D.
Alex Brown, Ph.D.
Eric Skaar, Ph.D., MPH
Michelle Sulikowski, Ph.D.
Gary Sulikowski, Ph.D., is the institute's new deputy director, succeeding Ned Porter, Ph.D., who stepped down last fall to focus on his research. Sulikowski also is associate director for Chemical Synthesis.
Other recently-named associate directors and their areas are Brian Bachmann, Ph.D., Molecular Discovery; Alex Brown, Ph.D., Systems Analysis; Eric Skaar, Ph.D., MPH, Translation/Therapeutics; and Michelle Sulikowski, Ph.D., Education.
The VICB was established in 2002 as a joint venture between the School of Medicine and the College of Arts and Science with support from the University's Academic Venture Capital Fund. Since then, it has established a high-throughput screening facility, a chemical synthesis facility, an antibody and protein resource and a small molecule NMR facility.
The institute also recruited several faculty members from leading universities and the pharmaceutical industry, and helped initiate neuroscience and cancer drug discovery programs.
Porter, Stevenson Professor of Chemistry and professor of Biochemistry, “played a critical role in building the VICB,” said Lawrence Marnett, Ph.D., the institute's founding director and University Professor of Biochemistry and Chemistry. Currently there are more than 70 VICB investigators representing 18 academic departments.
The associate directors are applying their diverse skill sets to creating new opportunities for discovery, Marnett said. One of the institute's goals is to enhance its screening collection of biologically active compounds by adding proteins and natural products to its collection of small molecules.
- Sulikowski, Stevenson Professor of Chemistry and professor of Biochemistry, is an expert in natural products synthesis and biosynthesis. His team has synthesized several anti-tumor antibiotics isolated from soil and marine microorganisms.
- Bachmann, an associate professor of Chemistry and Biochemistry, established the first systematic program to search for novel drugs produced by cave-dwelling microorganisms.
- Brown, professor of Pharmacology, pioneered the use of mass spectrometry, systems biology and other methods to track lipids in cells and tissues. He and his colleagues have helped define the role that lipid signaling pathways play in cancer.
Brown and VICB also are major participants in the Human Chemical Sciences Institute, a partnership of Vanderbilt University and The Scripps Research Institute “that seeks to accelerate the understanding of human chemistry in health and disease.”
- Skaar, associate professor of Microbiology & Immunology, studies the molecular mechanisms that make Staphylococcus aureus so dangerous. The goal is to find ways to block the bacterium from binding to hemoglobin in blood cells, and thereby prevent its ability to grow and cause infection.
- Michelle Sulikowski, Ph.D., senior lecturer in Chemistry, is co-investigator with her husband, Gary, of a National Science Foundation grant to provide chemical biology research experiences for undergraduates. She also oversees graduate education in the institute.
Due in part to the economy, “this is going to be a challenging period,” Marnett said. “Because of what we've built and the way science is evolving … (with) multiple collaborations (among) multiple disciplines, we should be well-positioned to compete effectively for funding,” he said. “But we'll have to work harder.”